247 related articles for article (PubMed ID: 34272304)
1. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
Sun H; Martin TG; Marra J; Kong D; Keats J; Macé S; Chiron M; Wolf JL; Venstrom JM; Rajalingam R
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272304
[TBL] [Abstract][Full Text] [Related]
2. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer.
Muraro E; De Zorzi M; Miolo G; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Dolcetti R; Steffan A; De Re V
Front Immunol; 2021; 12():791958. PubMed ID: 35095867
[TBL] [Abstract][Full Text] [Related]
3. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
Terszowski G; Klein C; Stern M
J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
6. Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19.
Maruthamuthu S; Rajalingam K; Kaur N; Morvan MG; Soto J; Lee N; Kong D; Hu Z; Reyes K; Ng D; Butte AJ; Chiu C; Rajalingam R
Front Genet; 2022; 13():845474. PubMed ID: 35273641
[No Abstract] [Full Text] [Related]
7. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
8. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation.
Gooneratne SL; Center RJ; Kent SJ; Parsons MS
Clin Exp Immunol; 2016 Apr; 184(1):101-9. PubMed ID: 26647083
[TBL] [Abstract][Full Text] [Related]
9. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos M; Bringhen S; Anttila P; Capra M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R
Blood; 2021 Mar; 137(9):1154-1165. PubMed ID: 33080623
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
11. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
Front Immunol; 2018; 9():704. PubMed ID: 29706958
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
13. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
[TBL] [Abstract][Full Text] [Related]
14. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
Front Immunol; 2020; 11():1771. PubMed ID: 32922390
[TBL] [Abstract][Full Text] [Related]
15. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
16. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
17. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.
Beelen NA; Ehlers FAI; Bos GMJ; Wieten L
Cancer Immunol Immunother; 2023 Apr; 72(4):797-804. PubMed ID: 36261539
[TBL] [Abstract][Full Text] [Related]
19. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
20. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
